Qingdao Haier Biomedical Co.Ltd(688139)
Proposal of independent directors on repurchase of shares of the company by means of centralized bidding transaction
Independent opinions on relevant matters
In accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”), the Listing Rules of science and Innovation Board of Shanghai Stock Exchange, the Qingdao Haier Biomedical Co.Ltd(688139) articles of Association (hereinafter referred to as the “articles of association”), the Qingdao Haier Biomedical Co.Ltd(688139) independent director system and other relevant laws and regulations As an independent director of Qingdao Haier Biomedical Co.Ltd(688139) (hereinafter referred to as “the company”), we have carefully reviewed the relevant proposals of the fifth meeting of the second board of directors of the company, and based on the principle of independent and objective judgment, we express the following independent opinions:
1. The shares repurchased by the company this time comply with the relevant provisions of laws, regulations and normative documents such as the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the opinions on supporting the repurchase of shares by listed companies, the rules for the repurchase of shares by listed companies, the guidelines for the self discipline supervision of listed companies of Shanghai Stock Exchange No. 7 – repurchase of shares, The voting procedures of the board meeting shall comply with relevant laws, regulations and the articles of Association; 2. The total amount of the company’s share repurchase funds shall not be less than 50 million yuan (inclusive) and not more than 100 million yuan (inclusive). The funds to be used for this repurchase are the company’s own funds, which will not have a significant impact on the company’s operation, finance and future development. The company is able to pay the repurchase price. After the repurchase, the equity distribution of the company meets the conditions of the listed company and will not affect the listing status of the company.
3. The implementation of the company’s share repurchase is conducive to safeguarding the interests of the company and shareholders, improving the company’s long-term incentive mechanism, fully mobilizing the enthusiasm of the company’s employees, and promoting the healthy and sustainable development of the company. The company’s share repurchase is necessary.
4. This repurchase is carried out in the form of centralized bidding transaction, and there is no situation that damages the interests of the company and all shareholders, especially small and medium-sized shareholders.
In conclusion, we believe that the company’s share repurchase is legal and compliant, and the repurchase plan is feasible and necessary, which is in line with the interests of the company and all shareholders.
February 2022: Zou Weijin, Chen Dianjie, independent director
